The Philadelphia Inquirer

A quick glance at the two skyscraper designs that Brandywine Realty Trust plans to submit to Philadelphia’s design review board in September makes it clear that all the usual expectations have been tossed out the windows at Schuylkill Yards.

The Philadelphia Inquirer

Developer Brandywine marks opening of park seen as first step toward big Schuylkill Yards project

Brandywine CEO Jerry Sweeney joined Philadelphia officials including Mayor Kenney to unveil the 1.3-acre Drexel Square park.

Philadelphia Business Journal

Spark CEO Marrazzo: Philadelphia will shine at BIO 2019

Jeff Marrazzo of Spark Therapeutics says Philadelphia can maximize our gene therapy momentum.

Philadelphia Business Journal

CSL Behring CEO: No better setting for BIO 2019 than Philadelphia

At BIO 2019, it’s all about scientific breakthroughs, innovative medicines, and helping patients overcome serious diseases.

The Philadelphia Inquirer

Updating an old newspaper building for Philadelphia’s new Schuylkill Yards innovation district

The Bulletin Building is a special part of West Philadelphia, so it will become a central piece of Schuylkill Yards.

The Philadelphia Inquirer

As construction starts at Philly’s Schuylkill Yards, New York’s Hudson Yards serves as a cautionary tale

The future is here. Three buildings will be under construction at Schuylkill Yards by the year’s end.


All the Details on Philly’s Newest Rooftop Destination, Opening Today

Sunset Social is now serving up burgers, brews, and spectacular views from Cira Green.

Philadelphia Business Journal

Drexel hits top rank for research institutions

Drexel has joined Temple and Penn in obtaining prestigious R1 status, the highest level a research university can reach in the key higher education classification system.

Nighttime aerial view of rooftop park Cira Green

Head to Cira Green, one of the most instagrammable places in Philly

It's official - take one for the 'gram 

Young employees gather together to look at a laptop screen
Philadelphia Business Journal

Roche to buy Spark Therapeutics for $4.8 billion

Swiss drug maker Roche entered into a definitive agreement Monday to acquire Philadelphia gene therapy pioneer Spark Therapeutics